Retinopathy of prematurity can progress before a baby has obvious symptoms. Record the zone, stage and vascular activity, arrange the next examination or treatment promptly, and secure written follow-up after discharge. Initial regression after anti-VEGF does not end surveillance.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Understand the immature retina and the competing risks
Retinopathy of prematurity (ROP), also called Retinopathia praematurorum (RPM), follows disturbed retinal vascular development after premature birth. Severe disease can lead to tractional retinal detachment and permanent visual loss; timely screening and treatment reduce that risk but cannot guarantee normal vision. 2
After birth, pulmonary gas exchange increases oxygen availability relative to the intrauterine environment. In the first phase, relative hyperoxia suppresses hypoxia-regulated growth signals, including vascular endothelial growth factor (VEGF), and interrupts normal vascular growth. 2
As the incompletely vascularised retina matures, its oxygen demand rises. The second phase, described around 32–34 weeks postmenstrual age (PMA), involves relative hypoxia, hypoxia-inducible factor 1 (HIF-1) and increased VEGF signalling. Excess disorganised vessels may grow beyond the retinal plane; accompanying fibrous tissue can contract and detach the retina. 2
Liver-derived insulin-like growth factor 1 (IGF-1) modulates vascular development. Poor nutrition or postnatal growth, necrotising enterocolitis (NEC) and sepsis can accompany low IGF-1; that association does not prove that replacement prevents ROP. 2 9
A phase 2 randomised IGF-1/IGFBP-3 replacement trial enrolled 121 infants born at 23+0–27+6 weeks:61 received treatment and 60 standard care. The regimen did not improve the primary ROP severity outcome; only 24 of 61 treated infants achieved target exposure. Secondary bronchopulmonary dysplasia findings do not establish a ROP-prevention indication or show that every future replacement strategy must fail. 9
Immaturity at birth is the main risk factor. Oxygen exposure matters, but oxygen is also life-saving neonatal treatment: never reduce prescribed supplementation independently to try to prevent ROP. 2 8
NeOProM combined individual data from five randomised trials in 4965 infants born before 28 weeks, comparing target oxygen saturation 85–89% with 91–95%. Death or major disability at 18–24 months occurred in 53.5% versus 51.6%; the trial-based risk difference was 1.7 percentage points (95% CI−1.3 to 4.6), with RR 1.04 (0.98–1.09), P=.21. This non-significant composite result does not establish equal safety. 8
Lower targets reduced treatment-requiring ROP:220/2020 (10.9%) versus 308/2065 (14.9%), risk difference−4.0 percentage points (95% CI−6.1 to −2.0). They also increased death, 484/2433 (19.9%) versus 418/2440 (17.1%), and severe NEC, 227/2464 (9.2%) versus 170/2465 (6.9%). These are different endpoint denominators; competing mortality and multiple secondary outcomes limit an isolated eye-focused interpretation. 8
The original “IGF-1 gatekeeper” is a useful growth-signal model, not an absolute switch: low IGF-1 may limit the vascular response despite VEGF, while later growth supports proliferation in a hypoxic retina. Neither this model nor an unqualified oxygen target of 88–92% establishes an individual neonatal oxygen prescription. Immaturity, systemic illness and survival compete with eye outcomes. 13 8 9
02Describe the zone, stage and vascular activity
The International Classification of Retinopathy of Prematurity, third edition (ICROP3), standardises the description. It is expert consensus, not a stand-alone treatment trial: combine the classification with the infant’s course and the applicable clinical guideline. 4
Zone I is centred on the optic disc, with a radius twice the disc-centre–fovea distance. With a 28 D lens, placing the nasal disc edge at the field edge helps approximate the temporal zone I boundary; this is an examination aid, not a replacement for careful localisation. 4
Zone II extends from zone I to the nasal ora serrata. ICROP3 defines posterior zone II as the region extending two disc diameters beyond the zone I boundary; the original shortcut using a radius of three disc–fovea distances is not equivalent. 4
Zone III is the remaining temporal crescent. Confirm that the nasal retina is vascularised to the ora serrata and that disease does not remain in the nasal two clock hours before assigning zone III; an apparently peripheral temporal lesion alone is insufficient. 4
Stage 1 is a demarcation line between vascularised and avascular retina; stage 2 is an elevated ridge. Stage 3 has extraretinal fibrovascular proliferation, which can be flat and difficult to recognise without an obvious ridge, particularly in aggressive disease. 4
Stage 4 is partial retinal detachment:4A leaves the fovea attached, whereas 4B involves the fovea. Stage 5 is total detachment, often funnel-shaped; ICROP3 further describes 5A with the disc visible, 5B without a visible disc, and 5C with additional anterior-segment changes. These findings require specialist retinal assessment. 4
Plus disease describes sufficiently severe vascular dilation and tortuosity; pre-plus lies between normal and plus on a continuum. The historical criterion uses at least two quadrants, while ICROP3 emphasises vascular assessment within zone I rather than a quadrant count alone. Observer variation remains relevant, so document the finding and uncertainty instead of treating the label as an infallible binary test. 2 4
Aggressive ROP (A-ROP), historically aggressive posterior ROP (AP-ROP or rush-type disease), may progress rapidly without the usual stage sequence. Marked plus changes, shunts, haemorrhage and a flat neovascular network can be disproportionate to the visible ridge. The newer name recognises that this pattern can occur beyond the posterior retina and in larger preterm infants. 2 4
ICROP3 was published in 2021, rather than the original “update 2022”. Zone I location increases concern but does not make every finding an automatic treatment indication. Plus is a vascular-severity assessment within the appropriate posterior field, not a rule to inspect only the immediate disc or ignore the peripheral front. A-ROP can progress without a conventional raised stage-3 ridge; do not wait for the textbook sequence. 13 4
03Keep eligibility, first examination and stopping rules separate
Screening criteria differ between countries and editions. The schedules below describe the directly inspected German 2020 guideline; the German July 2026 screening edition is located but its full clinical text has not yet been checked. These historical schedules must not be used as a verified 2026 protocol without that reconciliation. 1 2 3
The German 2020 guideline includes infants born before 31+0 gestational weeks, regardless of supplemental oxygen. If gestational age is uncertain, it uses birthweight below 1500 g. Its reduction from the previous 32+0 week boundary drew on a 2011–2018 registry series of 281 treated infants in which none had been born at 31+0 to<32+0 weeks; absence in that selected registry does not prove zero risk. 2
More mature preterm infants born before 37+0 weeks are considered when the neonatologist judges ROP risk, for example after more than 5 days of supplemental oxygen, extracorporeal membrane oxygenation (ECMO), severe NEC, bronchopulmonary dysplasia, sepsis or transfusion-requiring anaemia. The discretion and associated illnesses are part of the rule. 2
For untreated ROP, the German 2020 default interval is two weeks. Shorten to one week when the vascular front is in zone I or posterior zone II, irrespective of ROP stage; also use one-week intervals for anterior zone II stage 2 or 3 or any ROP with plus disease. Rapid progression or extreme immaturity can require even earlier examination. 2
The same historical schedule permits three-week intervals when the vascular front is in zone III without ROP. It permits adding one week after regression over several examinations or after the expected due date; these are conditional allowances, not automatic extensions for every infant. 2
Without treatment, historical German screening can end after complete circumferential peripheral vascularisation, or after clear peripheral regression only once the expected due date has passed. Discharge does not end the indication: severe disease can emerge after the baby has gone home. Treated infants need a separate follow-up plan. 2
Separate eligibility from the first examination. The original <31 weeks and/or <1500 g shorthand and 4 postnatal weeks or PMA 31–33 (whichever is later) are not interchangeable with the historical German 2020 schedule: first examination in postnatal week 6, days 36–42, not before PMA 31+0. PMA means gestational age at birth plus postnatal age. The claim “never earlier because biologically pointless” is too absolute across countries and clinical indications. The July 2026 German full text remains unread; do not adopt a historical schedule as current national guidance. 13 1 2 3
04Examine the whole vascular front and avoid artefacts
ROP screening requires an examiner experienced with premature infants, indirect ophthalmoscopy and ROP classification. Wide-field imaging can document findings and support telemedicine, but it must show the relevant peripheral retina; a limited image is not proof of a normal periphery. 2 3
A second person helps support the infant and head, with neonatal staff available. Topical anaesthetic before a speculum or lid hook and comfort measures such as non-nutritive sucking or glucose/sucrose reduce distress. Monitor the infant and keep the examination as brief as an adequate assessment permits. 2 3
Binocular indirect ophthalmoscopy permits stereoscopic assessment and gentle rotation to inspect the far peripheral vascular front. A speculum and scleral indentor may assist an experienced examiner; imaging equipment and reusable instruments require appropriate handling, disinfection and manufacturer guidance. 2 3
Use a consistent sequence: inspect the anterior segment and TVL first, then the central retina and finally the peripheral retina through 360 degrees. Record vascular extent, zone, stage, clock-hour extent, plus/pre-plus, haemorrhage and any traction or detachment. 2
Do not mistake reduced vessel calibre for true regression when arterial oxygen has changed or a camera has pressed too firmly on the eye. Distinguish retinal vessels from choroidal vessels when estimating vascularisation; posterior or aggressive disease can be underestimated if only a ridge is sought. 2
End every examination with a written decision: the next appointment, a treatment/referral plan with urgency, or documented satisfaction of stopping criteria. If the view is inadequate or the infant cannot tolerate a complete examination, arrange an explicit senior plan rather than recording the retina as normal. 2 3
A 28 D lens, speculum and gentle indentation can assist complete peripheral assessment; the original claim that examination is impossible without depression in every setting is too broad. Adequate views, neonatal stability and examiner expertise determine whether a method is sufficient. OCT can supplement morphological assessment but cannot replace localisation, plus assessment and the documented next examination. 13 2 4
05Treat the indication and interpret each trial separately
ETROP type 1 includes zone I ROP of any stage with plus, zone I stage 3 without plus, and zone II stage 2 or 3 with plus. Type 2 includes zone I stage 1 or 2 without plus and zone II stage 3 without plus and requires observation for progression. Distinguish this trial-derived framework from the original German 2020 discussion of zoneII 3+ treatment from one clock hour and from current national recommendations still being reconciled. 5
Once treatment is indicated, agree urgency with ophthalmology, neonatology and anaesthesia and explain the plan to the parents. Rapid aggressive disease may need treatment within 24 hours; ordinary scheduling must not delay an eye that is deteriorating quickly. 2 4 10
Laser photocoagulation treats the avascular peripheral retina and is an established option for treatment-requiring ROP. Cryotherapy remains relevant historically and in selected exceptional circumstances; comparison studies favoured laser outcomes. Laser leaves ablated peripheral retina, whereas anti-VEGF may permit further vascularisation but can leave persistent avascular areas and delayed reactivation. Intravitreal anti-VEGF treatment inhibits the VEGF signal driving pathological vessel activity; laser instead reduces the stimulus from treated avascular retina. 2 5 10
BEAT-ROP randomised 150 infants with bilateral stage 3+ ROP in zone I or posterior zone II to bevacizumab 0.625 mg/0.025 ml or laser. Among 143 survivors assessed toPMA 54 weeks, recurrence affected 6/140 eyes (4%;4 infants) versus 32/146 eyes (22%;19 infants), P=.002. The zone I signal was significant (P=.003), whereas posterior zone II was not (P=.27); seven deaths were excluded from the primary surviving cohort, and the trial was too small to establish safety. 6
FIREFLEYE provides randomised aflibercept evidence, correcting the old claim that it had only case reports or retrospective series. Of 118 randomised infants, 113 were treated:75 with aflibercept 0.4 mg and 38 with laser. At 24 weeks, success was 85.5% versus 82.1%; the difference was 3.4 percentage points, but the one-sided 95% Bayesian credible interval extended from −8.0 to∞against a −5 point margin. Non-inferiority was not met; this does not demonstrate inferiority, equivalence or superiority. 7
FIREFLEYE’s per-eye rescue rates, 4.8% versus 11.1%, use a different unit from infant-level primary success.104 infants completed the trial. Three deaths in the aflibercept arm were judged unrelated by investigators; small safety datasets cannot exclude uncommon systemic harm. Cross-trial percentages cannot establish the best anti-VEGF agent. 7
Drug approval and dose depend on the agent, formulation, indication and jurisdiction. Ranibizumab and aflibercept have EU ROP indications, so a blanket “anti-VEGF is off-label” statement is outdated; bevacizumab use remains distinct. The German S 1 v 1.2 records ranibizumab 0.2 mg/0.02 ml and corrected aflibercept 0.4 mg/0.01 ml. These small volumes require appropriate delivery; the current local product information and device instructions must be checked before treatment. The original also names conbercept; its current comparative evidence and local authorisation remain unverified here. Bevacizumab (Avastin), ranibizumab (Lucentis) and aflibercept (Eylea) must remain distinct agents, not interchangeable names or formulations. 10 11
Stages 4 and 5 may require vitrectomy and/or scleral buckling in a specialist retinal centre. Functional outcomes are generally poorer than after successful earlier treatment. Existing traction also matters when considering anti-VEGF because contraction can worsen the retinal configuration; surgery, drug treatment and laser need an individual plan. 2 10
The original “BUTTERFLY” corresponds to BUTTERFLEYE, a separate aflibercept trial. FDA’s 2023 reanalysis slide reports FIREFLEYE success 59/75 (79%) versus 31/38 (82%), difference −1.9 percentage points (95% CI −17 to 13), and BUTTERFLEYE 74/93 (80%) versus 21/27 (78%), difference 1.8 (−16 to 19). Neither met the −5-point noninferiority margin in that analysis. These definitions/analyses differ from FIREFLEYE’s published primary 85.5%/82.1%; they must not be mixed or presented as proven equivalence. Full BUTTERFLEYE protocol/peer-reviewed outcome report remains a source task. 14 7
The historical bevacizumab 0.625 mg/0.025 ml is not a universal half-adult-dose recipe. Likewise, the original entry exactly 1 mm behind the limbus is not certified for every infant, formulation and delivery device; lens and retinal injury prevention requires the current product/anatomy-specific specialist technique. A routine 48–72-hour framework cannot justify waiting in aggressive rapidly worsening ROP. Stage 4/5 visual prognosis is guarded, not invariably <0.1 or futile; anatomical attachment and functional recovery differ. 13 6 10
06Secure follow-up after regression and discharge
After laser, the historical German schedule starts with examinations at least weekly until activity has reliably regressed and all relevant avascular areas have been adequately treated. Intervals can then increase as the retina stabilises without active proliferation, traction or plus. Do not wait for complete vascularisation of retina that has been intentionally ablated. 2 10
After intravitreal anti-VEGF, arrange early postoperative checks for infection and injection-related complications. The inspected S1 text calls for at least one review within the first 4 days, assessing such concerns as perfusion, pressure, lens injury and retinal complications as appropriate; later reviews must still track disease activity. 2 10
When drug activity wanes, ROP can reactivate well after the expected due date or hospital discharge. Historical reports include recurrence atPMA 69 weeks or 35 weeks after the last injection. Neither number is a guaranteed safe stopping threshold, and early regression does not justify losing the infant to follow-up. 2 10
Historical German stopping options after anti-VEGF include complete vascularisation; adequate laser of residual avascular retina without treatment-requiring activity; or a stable inactive vascular pattern over several months despite residual avascular retina. The last option requires specialist judgment, explicit documentation and reconciliation with current guidance; persistent avascular retina is not automatically normal. 2 10
Use a written ROP-pass or equivalent handover containing treatment and examination dates, the latest findings, the receiving clinicians and the next appointment. Arrange that appointment before discharge and explain why missing it can allow silent progression. 2 3 10
Long-term care addresses refractive error, myopia, strabismus and visual development even after successful acute treatment. Later retinal or vascular changes can occur years afterwards, but a claim about late new vessels needs its specific context and source rather than assuming every treated child has ongoing acute ROP. Acute screening completion and long-term ophthalmic care are separate decisions. 2 3 12
The original PMA 45 weeks plus zone III/no ROP is not a universal stopping rule, particularly after anti-VEGF. Full peripheral maturation is one possible endpoint, not a demand that laser-ablated retina vascularise. Continue individual long-term assessment for myopia, strabismus, macular dragging and retinal detachment; document who takes responsibility when neonatal screening ends. 13 2 10
07Consider FEVR when the vascular pattern or course is atypical
Familial exudative vitreoretinopathy (FEVR) is a developmental retinal vascular disorder with variable inherited patterns and expression. It may present in term-born children with avascular peripheral retina, exudation, neovascularisation, folds, dragging or detachment, but prematurity does not exclude it. Atypical ROP, asymmetry, persistent avascularity or a family pattern can prompt reassessment; none alone proves FEVR. Negative family history does not exclude an inherited disorder. 13 16 15
Offer examination of immediate relatives and genetic counselling, with widefield FA or genetic testing chosen for the clinical question. A single-tertiary-practice retrospective series found many asymptomatic relatives with angiographic disease, supporting family assessment; selected referred families do not establish population prevalence or an identical invasive-test schedule for everyone. FEVR follow-up is disease- and life-course dependent, not governed by the ROP PMA stopping clock. 15 13
| Topic | Original teaching and correction | Next decision |
|---|---|---|
| First screening | Original 4 weeks or PMA 31–33; historical German 2020 week 6/days 36–42, not before 31+0 | Verify current 2026 full protocol; no biologically pointless absolute |
| Stopping | Original PMA 45 / zone III / no ROP is not universal | Post-anti-VEGF reactivation can be late; laser-ablated retina need not vascularise |
| Zone I | Radius 2 × disc–fovea distance | Posterior location increases concern, not every finding mandates treatment |
| Plus | Posterior vascular dilation/tortuosity on a continuum | Assess appropriate zone I field; do not ignore peripheral disease |
| Treatment | ETROP type 1: zone I any-plus or stage 3 no-plus; zone II stage 2/3 plus | Aggressive ROP needs urgent specialist treatment |
| Anti-VEGF | Bevacizumab 0.625 mg/0.025 ml is historical trial dose | Original 1 mm limbal entry not universal; product/anatomy-specific specialist technique |
| FEVR | Genetic developmental vascular disease, not restricted to term birth | Family assessment and counselling; selected imaging/testing, lifelong risk context |
What are the main learning points?
Retinopathy of prematurity can progress before a baby has obvious symptoms. Record the zone, stage and vascular activity, arrange the next examination or treatment promptly, and secure written follow-up after discharge. Initial regression after anti-VEGF does not end surveillance.
When is assessment urgent?
A white reflection in the pupil (leukocoria) needs immediate ophthalmic assessment: retinal detachment is one possible cause, and other serious causes must also be excluded. Marked jerking or unusual eye movements should be assessed promptly. Do not wait for the next routine appointment when a new worrying change appears.
References and access status
- 1DOG/AWMF 024-010 screening, July 2026 listing
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Current edition located through the official DOG listing; complete clinical text inaccessible. No agreement of the historical schedule with 2026 is claimed.
- 2German S2k ROP screening 2020, GNPI-hosted PDF
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual PDF downloaded; printedpp 1–17 clinical text/glossary and selected tables/references read. Historical guideline; figures/methods not all inspected. Original expired AWMF link retained in the source inventory.
- 3RCPCH UK screening summary, revised October 2024
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual recommendation summary printedpp 3–8 read; full guideline methods/appendices and later service pages unread. UK-specific, not a substitute for current German guidance.
- 4ICROP3, 2021; PMID 34247850
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract and selected downloaded preproof text pp 2–5/Table 1 read; actual printedp 3/Figure 1 visually inspected. Remaining figures/supplements/main text not completely read. Expert classification consensus.
- 5ETROP early treatment, 2003; PMID 14662586
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read. Main report, paired-eye analysis details, protocol and supplements unread; nine-month grating acuity is not long-term ordinary acuity.
- 6BEAT-ROP, 2011; PMID 21323540
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read. Full report/protocol/safety data unread. Recurrence by zone and eye/infant denominators must remain distinct.
- 7FIREFLEYE, 2022; PMID 35881122
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read.118 randomised/113 treated; non-inferiority not met. Main report/SAP/protocol and full safety data unread.
- 8NeOProM oxygen-target IPD meta-analysis, 2018; PMID 29872859
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read; full IPD methods, individual trial reports and supplements unread. Competing mortality, different endpoint denominators and multiple secondary endpoints matter.
- 9IGF-1/IGFBP-3 phase 2 randomised trial; PMID 30471715
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read; full report/protocol unread. Primary ROP outcome negative for the tested regimen; exposure attainment and secondary outcomes limit inference.
- 10German S1 ROP therapy 2025, v 1.2; corrected 12 January 2026
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Actual indexed title/TOC and selected clinical text printedpp 5–18 plus selected refs read. Direct local download was HTML denial, not PDF; figures/COI/methods not completely inspected. A suspected dilution inconsistency is documented in the evidence ledger; no recipe adopted.
- 11EMA Lucentis and product-specific EU ROP information
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Selected official Lucentis overview text read. Selected current English EMA Eylea ROP label access carried from parent 017 source work, not a new full 019 label pass. Complete current German product information/device instructions remain pending; see evidence ledger for Eylea source.
- 12RAINBOW five-year extension, 2024; PMID 38638400
Historical 019-retinopathy-prematurity appraisal reused; not new full-source access. Complete indexed abstract read; full tables/protocol unread. Extension selection, attrition and differing vision tests limit inference. The abstract OR direction for high myopia needs full-table clarification; raw counts are retained instead.
- 13Immutable original export; own ROP/FEVR lecture; examiner voice and recording unchecked
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 14FDA aflibercept ROP advisory committee, 9 January 2023
Actual primary indexed slide 21 endpoint reanalysis read 17 November 2026; full briefing/IFU not appraised. FDA reanalysis differs from published FIREFLEYE primary definition.
- 15Kashani et al., FEVR family-member vascular anomalies; PMID 24084499
Primary indexed objective/methods/results/conclusion read 17 November 2026; single tertiary-practice retrospective series. Direct PubMed incomplete; full report/figures not appraised.
- 16Genotypic distribution/clinical correlations in FEVR, 2025; PMID 40458664
Primary indexed title/design and inclusion of a small premature atypical-ROP cohort read 17 November 2026; full abstract, genetic tables and report unread.
Original lecture link
For patients
In babies born very early, the blood vessels of the retina have not finished developing. Prematurity, oxygen balance and other illnesses can disturb this process. Oxygen may be essential treatment: parents should not alter it themselves and are not to blame for ROP.
The condition may progress without obvious symptoms, so attend every eye appointment even after treatment has initially worked. Tell the team about unusual eye movements or squinting; glasses or other visual support may help the child’s visual development.
Before discharge, ask for the latest findings, treatment details and next appointment in writing. The team decides whether laser, an injection or retinal surgery is needed and how long follow-up should continue; this information cannot replace an individual examination and treatment plan.
A white reflection in the pupil (leukocoria) needs immediate ophthalmic assessment: retinal detachment is one possible cause, and other serious causes must also be excluded. Marked jerking or unusual eye movements should be assessed promptly. Do not wait for the next routine appointment when a new worrying change appears.